Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.485
-0.190-3.35%
Volume:82.18M
Turnover:461.49M
Market Cap:102.48B
PE:36.10
High:5.865
Open:5.560
Low:5.475
Close:5.675
52wk High:8.335
52wk Low:4.136
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:1.89
T/O Rate:0.44%
Dividend:0.12
Dividend Rate:2.24%
EPS(LYR):0.152
ROE:14.07%
ROA:7.51%
PB:2.69
PE(LYR):36.10
PS:2.60

Loading ...

Movement Alert|SBP GROUP Declines 3.08% in Regular Trading, Trading at 5.67 HKD

Market Focus
·
Sep 09

SBP Group Unveils Preclinical Findings for Oral STAT6 Degrader TQH5528 at ERS 2026

Stock News
·
Sep 08

Sino Biopharm Presents ERS 2026 Preclinical Data for Oral STAT6 Degrader Tqh5528

Reuters
·
Sep 08

Sino Biopharm CEO Tse Says AI, Internationalization Anchor Counter-Cyclical Growth Strategy

Reuters
·
Sep 08

Movement Alert|SBP GROUP Rises 3.02% in Regular Trading, TQC3721 Inhaler Phase I Clinical Data Presented at European Respiratory Society Annual Meeting

Market Focus
·
Sep 08

Hong Kong Stock Market Update | SBP GROUP (01177) Climbs Nearly 3% After TQC3721 Inhalation Powder Data Presented at ERS 2026

Stock News
·
Sep 08

SBP Group Unveils Positive Phase I Data for TQC3721 Dry-Powder Inhaler at ERS 2026

Bulletin Express
·
Sep 07

Sino Biopharma Reports Phase I Data Showing Tqc3721 Dry Powder Inhaler Boosts COPD Lung Function in Dose-Ranging Trial

Reuters
·
Sep 07

Sino Biopharmaceutical Stock Slides 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 07

Wuhan Dazhong Dental Proposes Wang Hong as Executive Director to Replace Guo Jiaping

Reuters
·
Sep 04

Sino Biopharma Gets US FDA Investigational New Drug Approval for Tumor Drug

MT Newswires Live
·
Sep 04

Sino Biopharm Says FDA Clears IND for Tqb6426 GPC3 ADC Trial in Advanced Tumors

Reuters
·
Sep 03

Sino Biopharmaceutical - Application for Clinical Trial on Tqb6426 "Gpc3 ADC" Approved by FDA

THOMSON REUTERS
·
Sep 03

Sino Biopharmaceutical Stock Rises 6.3% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 03

SBP Group Surges Over 4% in Morning Trade on FDA Clearance for TQB6426

Deep News
·
Sep 03

Movement Alert|SBP GROUP Rises 3.33% in Regular Trading, Core ADC Drug TQB2102 Phase III Trial Hits Primary Endpoint

Market Focus
·
Sep 03

Sino Biopharm Files HKEX Next-Day Return Disclosing Share Buyback for Cancellation

Reuters
·
Sep 01

SBP Group Reports No Share Changes in August; 14.60 Million Shares Earmarked for Future M&A Payout

Bulletin Express
·
Sep 01

Sino Biopharma Unit Enters License, Supply Contract for Cancer Drug

MT Newswires Live
·
Aug 31

SBP Group inks exclusive pact with Cipla for novel HER2-targeting ADC

Stock News
·
Aug 31